[HTML] plos.org

[HTML][HTML] Mechanism of resistance and novel targets mediating resistance to EGFR and c-Met tyrosine kinase inhibitors in non-small cell lung cancer

GM Botting, I Rastogi, G Chhabra, M Nlend, N Puri - PloS one, 2015 - journals.plos.org
Tyrosine kinase inhibitors (TKIs) against EGFR and c-Met are initially effective when
administered individually or in combination to non-small cell lung cancer (NSCLC) patients …
被引用次数：51 相关文章
[PDF] semanticscholar.org

[PDF][PDF] Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

GM Botting, I Rastogi, G Chhabra, M Nlend… - PLoS …, 2015 - pdfs.semanticscholar.org
Tyrosine kinase inhibitors (TKIs) against EGFR and c-Met are initially effective when
administered individually or in combination to non-small cell lung cancer (NSCLC) patients …

[引用][C] Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

GM Botting, I Rastogi, G Chhabra, M Nlend… - PLoS ONE, 2015 - ui.adsabs.harvard.edu
Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met
Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer - NASA/ADS Now on home page …
[PDF] psu.edu

[PDF][PDF] Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

GM Botting, I Rastogi, G Chhabra, M Nlend, N Puri - PLoS ONE, 2015 - Citeseer
Tyrosine kinase inhibitors (TKIs) against EGFR and c-Met are initially effective when
administered individually or in combination to non-small cell lung cancer (NSCLC) patients …

Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.

GM Botting, I Rastogi, G Chhabra, M Nlend… - PLoS ONE, 2015 - search.ebscohost.com
Tyrosine kinase inhibitors (TKIs) against EGFR and c-Met are initially effective when
administered individually or in combination to non-small cell lung cancer (NSCLC) patients …
[PDF] researchgate.net

[PDF][PDF] Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

GM Botting, I Rastogi, G Chhabra, M Nlend, N Puri - PLoS ONE, 2015 - researchgate.net
Tyrosine kinase inhibitors (TKIs) against EGFR and c-Met are initially effective when
administered individually or in combination to non-small cell lung cancer (NSCLC) patients …

Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

GM Botting, I Rastogi, G Chhabra, M Nlend, N Puri - PLoS ONE, 2015 - go.gale.com
Tyrosine kinase inhibitors (TKIs) against EGFR and c-Met are initially effective when
administered individually or in combination to non-small cell lung cancer (NSCLC) patients …

[引用][C] Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

GM Botting, I Rastogi, G Chhabra, M Nlend, N Puri - PLOS ONE, 2015 - cir.nii.ac.jp
Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine
Kinase Inhibitors in Non-Small Cell Lung Cancer | CiNii Research CiNii 国立情報学研究所 学術 …

Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.

GM Botting, I Rastogi, G Chhabra, M Nlend, N Puri - Plos one, 2015 - europepmc.org
Tyrosine kinase inhibitors (TKIs) against EGFR and c-Met are initially effective when
administered individually or in combination to non-small cell lung cancer (NSCLC) patients …
[HTML] nih.gov

[HTML][HTML] Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

GM Botting, I Rastogi, G Chhabra, M Nlend, N Puri - PLoS ONE, 2015 - ncbi.nlm.nih.gov
Tyrosine kinase inhibitors (TKIs) against EGFR and c-Met are initially effective when
administered individually or in combination to non-small cell lung cancer (NSCLC) patients …